Related Experiment Video

Updated: Feb 20, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma

A G Solimando1,2,3, A Brandl1,2, K Mattenheimer1,2

  • 1Department of Internal Medicine II, Interdisciplinary Center for Clinical Research Laboratory, University Hospital of Würzburg, Würzburg, Germany.

Leukemia
|October 25, 2017
PubMed

Insights

Junctional adhesion molecule-A (JAM-A) is crucial for multiple myeloma (MM) cell survival and drug resistance. Targeting JAM-A shows promise for MM treatment and offers a potential biomarker for disease stratification.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Cell adhesion in the multiple myeloma (MM) microenvironment promotes MM cell survival and drug resistance.
  • Junctional adhesion molecule-A (JAM-A) is investigated as a potential therapeutic target and biomarker in MM.

Purpose of the Study:

  • To evaluate the role of JAM-A in MM pathogenesis and its potential as a therapeutic target and biomarker.
  • To assess JAM-A expression in MM cells and patient samples and its correlation with disease progression.

Main Methods:

  • JAM-A expression was analyzed in MM cell lines and 147 MM patient bone marrow aspirates and biopsies.
  • In vitro functional assays assessed the impact of JAM-A inhibition on MM cell behavior.
  • In vivo studies utilized a murine xenograft MM model treated with an anti-JAM-A monoclonal antibody (αJAM-A moAb).

Main Results:

  • Elevated JAM-A levels in patient plasma cells correlated with poor prognosis.
  • Circulating soluble JAM-A (sJAM-A) levels were significantly higher in MM patients.
  • In vitro JAM-A inhibition reduced MM cell migration, colony formation, chemotaxis, proliferation, and viability.
  • In vivo treatment with αJAM-A moAb impaired tumor progression in a murine MM model.

Conclusions:

  • JAM-A plays a significant role in multiple myeloma progression and drug resistance.
  • Targeting JAM-A therapeutically holds potential for preventing MM progression.
  • JAM-A and sJAM-A are proposed as valuable biomarkers for MM clinical stratification.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K